Moderna (MRNA) PT Raised to $150 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $228.44 +3.45%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham raised the price target on Moderna (NASDAQ: MRNA) to $150.00 (from $140.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Moderna (MRNA) call put ratio 1 call to 1 put into quarter results
- Celanese (CE) PT Raised to $65 at Citi
- COPT Defense Properties (CDP) PT Lowered to $36 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
